Genmab is an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.

First Quarter 2016 Financial Results

Genmab will report its First Quarter 2016 financial results after market close on May 10.  An investor conference call to discuss the results will be held at 6:00 PM CEST / 12:00 PM EDT on May 10. To join the call by phone, dial one of the following numbers and ask for the Genmab conference call: +4538 48 75 13 in Denmark, +44 20 3427 1917 in the UK or +1 212 444 0412 in the US. Click here to listen to the webcast. 

Join our teamCareer Opportunities at Genmab

Genmab is seeking new employees to join our teams in Copenhagen and Utrecht. Visit our Careers web pages to explore our current vacancies, learn about our culture and meet some of our team members

Our Technologies Explained

Learn about Genmab’s proprietary cutting edge technologies, the DuoBody® and HexaBody® platforms at our new technology website